Subscribe to RSS
DOI: 10.1055/s-0035-1553717
Halluzinogen-induzierte Persistierende Wahrnehmungsstörung (HPPD) und Flashback-Phänomene – Differenzialdiagnose und Erklärungsmodelle
Hallucinogen Persisting Perception Disorder (HPPD) and Flashback Phenomena – Differential Diagnosis and Explanation ModelsPublication History
03 July 2015
14 August 2015
Publication Date:
30 September 2015 (online)
![](https://www.thieme-connect.de/media/fdn/201509/lookinside/thumbnails/fdnp-668_10-1055-s-0035-1553717-1.jpg)
Zusammenfassung
Ziel dieser Arbeit ist es, einen Überblick über den Forschungsstand bezüglich „Halluzinogen-induzierter persistierender Wahrnehmungsstörung, HPPD“ und „Flashback“-Phänomenen zu geben. Die diagnostischen Merkmale und Begriffe von „Flashback“-Phänomenen und „HPPD“ nach Halluzinogeneinnahme blieben bis heute unklar und wurden seit 1994 austauschbar verwendet.
Methode: Die Literaturauswahl erfolgte mittels einer MEDLINE-Datenrecherche der Jahrgänge 1994 – 2014 mit den Suchbegriffen „Hallucinogen Persisting Perception Disorder“ (HPPD) sowie durch Sichtung weiterführender Literaturhinweise. Von weit über 100 Literaturhinweisen wurden schließlich 75 Artikel in die Auswertung einbezogen.
Ergebnisse: In Übereinstimmung mit ICD-10-Definition (F16.70) „Nachhallzustände“ (Flashback) wird der Begriff oft benutzt, um eine kurzdauernde visuelle Wahrnehmung, eine veränderte Stimmung und einen veränderten Bewusstseinszustand zu beschreiben, die den Wirkungen einer akuten Halluzinogenintoxikation entsprechen. Viele Halluzinogenkonsumenten bewerten Flashback-Phänomene positiv und teilweise als angenehm. HPPD wird im DSM-5 als visuelle Wahrnehmungsstörung beschrieben, die manchmal Monate bis Jahre persistiert und im individuellen Fall massive Stressbelastungen zur Folge hat. Die Prävalenz von HPPD ist unbekannt. Es ist erstaunlich, dass angesichts der Millionen Halluzinogenkonsumenten seit den 60er und 70er Jahren relativ wenige Kasuistiken publiziert wurden. Trotz der Vielfalt ätiologischer und therapeutischer Ansätze sind die bei HPPD zugrunde liegenden pathophysiologischen Mechanismen schwer zu fassen. Gegenwärtig scheint HPPD weiterhin ein DSM-5-genuines, aber immer noch rätselhaftes Störungsbild zu sein. Die verschiedenen Folgewirkungen und neue ätiologische und therapeutische Ansätze werden praxisrelevant dargestellt.
Abstract
Objective: The purpose of this article is to provide an overview of the current research on “Hallucinogen Persisting Perception Disorder” (HPPD) and “Flashback” phenomena. The definition and diagnostic features of “Flashback” and HPPD remained often unclear and since the 1960 s interchangeable.
Methods: Relevant literature was identified by means of a computerized MEDLINE search including the years 1994 – 2014. Finally 75 journal articles out were included in the review.
Results: Consistent with the ICD-10 (F16.70) definition “Flashback” is often used to describe brief visual perceptual, mood, and altered states of consciousness effects reminiscent of acute hallucinogen intoxication effects. Many users regard flashback phenomena as benign and even pleasant. HPPD is described in DSM-5 as a visual perceptual disorder, sometimes persisting for months or years causing severe individual distress. The prevalence of flashback and HPPD is unknown. It is considered to be remarkable in view of the relatively few case reports published out of millions of hallucinogen users since the 1960 s and 1970 s. Despite a multitude of etiological and therapeutic approaches the exact pathophysiological mechanisms underlying HPPD remain elusive. At present HPPD appears to be further a DSM-5-genuine but still puzzling disorder. The different consequences including new therapeutic approaches are discussed in clinical context.
-
Literatur
- 1 Sandison RA, Spencer AM, Whitelaw JDA. The therapeutic value of lysergic acid diethylamid in mental illness. J MentSci 1954; 100: 491
- 2 Cooper H. Hallucinogenic drugs. Lancet 1955; 1: 1078-1079
- 3 Eisner B, Cohen S. Psychotherapy with lysergic acid diethylamid. J Nerv Ment Dis 1958; 127: 528-539
- 4 Woody G. Visual Disturbances Experienced by hallucinogenic drug abusers while driving. Amer J Psychiatry 1970; 127: 683-685
- 5 Hasse HE, Waldmann H. „Flashback“. Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiat Nervenkr 1971; 214: 399-439
- 6 McGlothlin H, Arnold D. LSD revisited: A ten-year Follow-up of medical LSD use. Arch Gen Psychiat 1971; 24: 35-49
- 7 Matefy RE, Krall RC. Psychedelic drug flashbacks: psychotic manifestation or imaginative role playing. J Consult Clin Psychology 1975; 43: 434
- 8 Wesson D, Smith D. An analysis of psychedelic drug flashbacks. Amer J Drug Alcohol Abuse 1976; 3: 425-438
- 9 Fischer J, Täschner KL. Flashback nach Cannabiskonsum – eine Übersicht. Fortschr Neurol Psychiat 1991; 59: 437-446
- 10 Rosenthal S. Persistent hallucinosis following repeated administration of hallucinogenic drugs. Amer J Psychiatry 1964; 121: 238-244
- 11 Fisher DD, Ungerleider JT. The therapy of untoward LSD reactions. Current Psychiatric Therapies 1968; 8: 110-114
- 12 Horowitz MJ. Flashbacks: Recurrent intrusive images after the use of LSD. Am J Psychiatr 1969; 126: 565-569
- 13 Bron B. Drogenabhängigkeit und Psychose. Berlin: Springer; 1982
- 14 Dilling H, Mombour W, Schmidt MH Hrsg. Internationale Klassifikation psychischer Störungen. Klinisch-diagnostische Leitlinien nach Kapitel V(F) der ICD-10. Bern: Huber; 2000
- 15 Ungerleider JD, Fisher D, Goldsmith SR et al. A statistical survey of adverse reactions to LSD in Los Angeles county. Am J Psychiatry 1968; 124: 352-357
- 16 Blumenfield M. Flashback phenomena in basic trainees who enter the US Air Force. Milit Med 1971; 136: 39-41
- 17 Moskowitz D. Use of haloperidol to reduce LSD flashbacks. Milit Med 1971; 136: 754-756
- 18 Stanton M, Bardoni A. Drug flashbacks: reported frequency in a military population. Amer J Psychiat 1972; 129: 751-755
- 19 Holsten F. Flashbacks: A personal follow-up. Arch Psychiat Nervenkr 1976; 222: 293-304
- 20 McGee R. Flashbacks and memory phenomena: a comment on “Flashback phenomena – clinical and diagnostic dilemmas”. J Nerv Ment Dis 1984; 172: 273-278
- 21 Alarcon RD, Dickinson WA, Dohn HH. Flashback phenomena: clinical and diagnostic dilemmas. J Nerv Ment Dis 1982; 170: 217-223
- 22 Halpern JH. Hallucinogens: An update. Curr Psychiatry Rep 2003; 5: 347-354
- 23 Halpern JH, Pope HG. Hallucinogen persisting perception disorder: what do we know after 50 years. Drug Alcohol Depend 2003; 69: 109-119
- 24 Holland D, Passie T. Flashback-Phänomene. Berlin: VWB-Verlag für Wissenschaft und Bildung; 2011
- 25 Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis 1960; 130: 30-40
- 26 Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 1971; 118: 229-230
- 27 Halpern JH, Sherwood AR, Hudson JI et al. Psychological and cognitive effects of long-term peyote use among native Americans. Biol Psychiatry 2005; 58: 624-631
- 28 Abraham HD, Aldridge AM, Gogia P. The psychopharmacology of hallucinogens. Neuropsychopharmacology 1996; 14: 285-298
- 29 American Psychiatric Association. Diagnostic and statistical manual of mental disorders: (DSM-5). 5 ed. Arlington, VA: American Psychiatric Association; 2013
- 30 Falkai P, Wittchen HU Hrsg. Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5. Deutsche Ausgabe. Göttingen: Hogrefe; 2014
- 31 Bagott MJ, Coyle JR, Erowid E et al. Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend 2011; 114: 61-67
- 32 Espiard ML, Lecardeur L, Abadie P et al. Hallucinogen persisting disorder after psilocybin consumption: a case study. Eur Psychiatry 2005; 20: 458-460
- 33 Studerus E, Kometer M, Hasler F et al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacology 2011; 25: 434-452
- 34 Hermle L, Kovar KA, Hewer W et al. Halluzinogen-induzierte psychische Störungen. Fortschr Neurol Psychiatr 2008; 76: 334-342
- 35 Hermle L, Simon M, Ruchsow M et al. Hallucinogen-persisting perception disorder. Ther Adv Psychopharmacol 2012; 2: 199-205
- 36 Abraham HD. A chronic impairment of colour vision in users of LSD. Br J Psychiatry 1982; 140: 518-520
- 37 Abraham HD. Visual phenomenology of the LSD flashback. Arch Gen Psychiatry 1983; 40: 884-889
- 38 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IVTR). 4th ed. Washington DC: American Psychiatric Press; 1994
- 39 Pechnik RN, Ungerleider JT. Hallucinogens. In: Lowinson JH, Ruiz P, Milman RB, et al. eds. Substance abuse: a comprehensive textbook. 4th edition. Baltimore: Lippincott Williams & Wilkins; 2004: 313-323
- 40 Keeler MH, Reifler CB, Liptzin MB. Spontaneous recurrence of Marihuana effect. Am J Psychiatry 1968; 125: 140-142
- 41 Yager J, Crumpton E, Rubenstein R. Flashbacks among soldiers discharged as unfit who abused more than one drug. Am J Psychiatry 1983; 140: 857-861
- 42 Hughes MS, Lessell S. Trazodone-induced palinopsia. Arch Ophtalmol 1990; ¸ 108: 399-400
- 43 Faber RA, Benzick JM. Nefazodone-induced palinopsia. J Clin Psychopharmacol 2000; 20: 275-276
- 44 Lauterbach EC, Abdelhmid A, Annandale JB. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5-HT2a receptor blockade. Pharmacopsychiatry 2000; 33: 38-41
- 45 Ihde-Scholl T, Jefferson JW. Mirtazapine-associated palinopsia. J Clin Psychiatry 2001; 62: 373
- 46 Evans RW. Reversible palinopsia and the Alice in Wonderland syndrome associated with topiramate use in migraineurs. Headache 2006; 46: 815-818
- 47 Fontenelle LF. Topiramate-induced palinopsia. J Neuropsychiatry Clin Neurosc 2008; 20: 249-250
- 48 Abraham HD, Aldridge AM. Adverse consequences of LSD. Addiction 1993; 88: 1327-1334
- 49 Abraham HD, Duffy FH. Stable EEG differences in post-LSD visual disorder by split half analyses: Evidence for disinhibition. Psychiatry Research: Neuroimage 1996; 67: 173-187
- 50 Fischer R. A cartography of the ecstatic and meditative states. Science 1971; 174 (4012) 897-904
- 51 Assmus H, Reimer F. Accidental LSD intoxication of three brothers and sisters in childhood with “echo-psychosis”. Praxis der Kinderpsychologie und Kinderpsychiatrie 1972; 21: 207-209
- 52 Kilpatrick ZP, Ermentrout GB. Hallucinogen persisting perception disorder in neuronal networks with adaptation. J Comput Neurosci 2012; 32: 25-53
- 53 Abraham HD, Mamen A. LSD-like paic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996; 16: 238-241
- 54 Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997; 58: 85
- 55 Lerner AG, Oyffe I, Isaacs G et al. Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1997; 154: 437
- 56 Lerner AG, Gelkopf M, Oyffe I et al. LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharmacol 2000; 15: 35-37
- 57 Lerner AG, Skladman I, Kodesh A et al. LSD-induced Hallucinogen Persisting Disorder treated with clonazepam: two case reports. Isr J Psychiatry Relat Sci 2001; 38 (02) 133-136
- 58 Aldurra G, Crayton JW. Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: Case Report. J Clin Psychopharmacol 2001; 21: 343-344
- 59 Lerner AG, Shufman E, Kodesh A et al. Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse. Isr J Psychiatry Relat Sci 2002; 39: 57-60
- 60 Lerner AG, Gelkopf M, Skladman I et al. Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol 2003; 18: 101-105
- 61 Markel H, Lee A, Holmes RD et al. LSD flashback syndrome exacerbated by elective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 1994; 125: 817-819
- 62 Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology 1996; 14: 425-436
- 63 Hermle L, Simon M, Ruchsow M et al. Hallucinogen persisting perception disorder (HPPD) and flashback – are they identical. J Alcoholism Drug Depend 2013; 1: 121 DOI: 10.4172/2329-6488.1000121.
- 64 Halonen T, Nissinen J, Pitkänen A. Effect of lamotrigine treatment on status epilepticus-induced neuronal damage and memory impairment in rat. Epilepsy Res 2001; 46: 205-223
- 65 Weil AT. Adverse reactions to marijuana: classification and suggested treatment. N Engl J Med 1970; 282: 997-100
- 66 Batzer W, Ditzler T, Brown C. LSD use and flashbacks in alcoholic patients. J Addict Dis 1999; 18: 57-63
- 67 Strassman RJ. Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis 1984; 172: 577-595
- 68 Abraham HD. New hope for hallucinogen-induced persistent perceptual disorder? (Letter). J Clin Psychopharmacol 2001; 21: 344
- 69 Lerner AG, Goodman C, Bor O et al. Synthetic cannabis substances (SPS) use and hallucinogen persisting perception disorder (HPPD): two case reports. Isr J Psychiatry Relat Sci 2014; 51: 277-280
- 70 Lerner AG, Lev-Ran S. LSD-associated “Alice in Wonderland Syndrome” (AIWS): A hallucingen persisting perception disorder (HPPD) case report. Isr J Psychiatry Relat Sci 2015; 52: 67-69
- 71 Lerner AG, Goodman C, Rudinski D et al. LSD flashbacks – the appearance of new visual imagery not experienced during initial intoxication: two case reports. Isr J Psychiatry Relat Sci 2014; 51: 307-309
- 72 Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 1998; 80-84
- 73 Lerner AG, Rudinski D, Bor O et al. Flashbacks and HPPD: A clinical-oriented concise review. Isr J Psychiatry Relat Sci 2014; 51: 296-302
- 74 Frankel FH. The concept of flashbacks in historical perspective. Int J Clin Exp Hypn 1994; 42: 321-336
- 75 Papst AE, Kraus L, Gomes de Matos E et al. Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012. Sucht 2013; 59: 321-331